Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's eMDR program will soon be mandatory

This article was originally published in The Silver Sheet

Executive Summary

FDA is urging device manufacturers to begin using the agency's electronic Medical Device Reporting (eMDR) program in anticipation that they will be required to do so as early as next spring. Currently, the eMDR program - which aims to improve CDRH's ability to analyze adverse event reports so it can identify troubling patterns more efficiently - is voluntary ("The Silver Sheet" August 2007). However, that will change once the agency issues a final rule on the program early next year, Don St. Pierre, CDRH associate director for postmarket transformation, said Sept. 25 at the Regulatory Affairs Professionals Society (RAPS) annual conference in Boston. "You can do [electronic reporting] now or you can wait for it to be done to you," he said, noting that so far only 15 eMDRs have been filed with FDA, all by one company

You may also be interested in...



Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Dr Reddy’s And Hikma Win Big On US Vascepa Patents

In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.

Manipulating Metabolism: Lilly Links With UK Biotech Sitryx

Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.

Topics

UsernamePublicRestriction

Register

MT036147

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel